Back to Atlas
CTransientStandard research/education caution
CMP-0308
Approved
Danazol / Danocrine
Endocrine / AAS-adjacent
Suppresses gonadotropins; not a muscle-building AAS in practice
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Synthetic steroid / weak androgen
- Primary mechanism
- Weak androgen/progestogenic-antigonadotropic effects; A:A ratio not meaningful
- Primary market use
- Endometriosis/hereditary angioedema history
Pharmacology
- Molecular weight (Da)
- 337.46
- Oral bioavailability
- Oral; clinically active
- Half-life
- ~24 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved
- Clinical status
- Approved
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Included because MESO lists it under steroid profiles; categorize as endocrine/AAS-adjacent rather than anabolic-builder.